Milestone Scient Stock Price, News & Analysis

Milestone Scientific (NYSE:MLSS) announced the successful commencement of sales for its CompuFlo Epidural disposables at a prominent Southern California medical center recognized for maternity care. This facility is part of a large healthcare system that delivers over 100,000 babies annually. CEO Arjan Haverhals highlighted the company's growing presence in the labor market. Additionally, the AMA has approved a new CPT code for the CompuFlo system, expected to enhance commercialization in various markets, including pain management.

Milestone Scientific (NYSE:MLSS) announced the issuance of a new Category III CPT code by the American Medical Association for its CompuFlo Epidural System. This code, effective January 1, 2023, aims to enhance reimbursement opportunities for epidural procedures. The CPT Editorial Panel validated the technology based on clinical studies, which indicate improved accuracy and reduced complications in pain management. CEO Arjan Haverhals highlighted the potential of this development to accelerate commercial rollout and increase market penetration, especially in the chronic pain segment.

Milestone Scientific (NYSE: MLSS) announced the initiation of sales for its CompuFlo Epidural instrument at a prominent veterinary and academic institution. This follows a successful evaluation of the device in maxillary nerve block procedures in horses. The instrument enhances accuracy in nerve block applications and aims to improve the training of upcoming veterinarians. CEO Arjan Haverhals expressed confidence in the commercialization of their technology across various medical sectors, emphasizing the potential for improved patient outcomes and broad market applicability.

Milestone Scientific (NYSE: MLSS) has appointed Ms. Benedetta Casamento to its Board of Directors. Casamento, a retail consultant with extensive experience in finance and brand management, was previously Chairman and President of Allyke, Inc., and has held top roles at Calypso St. Barth and The Talbots. Her expertise in marketing and operations is expected to bolster Milestone's growth strategies, particularly for its CompuFlo® Epidural and CathCheck™ products. Chairman Leslie Bernhard expressed confidence in her potential contributions to the company’s future.

Milestone Scientific Inc. (NYSE: MLSS) reported Q1 2022 revenues of $2.7 million, down from $2.9 million in Q1 2021. The decrease was attributed to prior year's pent-up demand. Despite the decline, the company is advancing sales efforts for its CompuFlo® Epidural and CathCheck™ systems and has secured vendor status with a major Northeast hospital. Operating loss rose to $(1.9) million. However, Milestone maintains a strong balance sheet with $13.3 million in cash and is well-positioned for growth, particularly in the dental segment amid expanding distribution partnerships.

Milestone Scientific Inc. (NYSE:MLSS) will host a conference call on May 17, 2022, at 8:30 AM ET to discuss its financial results for Q1 2022, ending March 31. The call aims to provide insights into the company's corporate progress and developments. U.S. callers can join by calling toll-free 888-506-0062, and international callers can reach +1 973-528-0011. An audio replay will be available until May 31, 2022. Milestone Scientific specializes in innovative injection technologies, enhancing patient comfort and safety.

Milestone Scientific (NYSE:MLSS) announced that its President and CEO, Arjan Haverhals, will present at the Noble Capital Markets Eighteenth Annual Investor Conference on April 21, 2022, at 11:30 am ET in Seminole Ballroom D. Investors can meet management at breakout sessions on April 20. A video webcast of the presentation will be available the following day on the company’s website and other platforms for 90 days. Milestone specializes in advanced drug delivery systems, enhancing patient comfort and safety through innovative technologies.

Milestone Scientific Inc. (NYSE: MLSS) has formed a strategic partnership with Keystone Dental Group to enhance the distribution of its STA Single Tooth Anesthesia® system in the dental implant market. This collaboration leverages Keystone's sales force of over 60 representatives to expand reach into surgical specialties. Additionally, Milestone has partnered with American Independent Dental Alliance to access over 1,000 dental practices, and with Esthetic Professionals to enhance dental education through hands-on training. These initiatives aim to drive growth in the expanding DSO market.

Milestone Scientific (NYSE: MLSS) has begun sales of its CompuFlo Epidural and CathCheck Verification System to a leading medical center recognized as one of the World’s Best Hospitals-USA for four consecutive years. The approval comes after a successful evaluation and emphasizes the systems' clinical advantages in improving accuracy and reducing complication rates during epidural procedures. These innovations aim to drive better health outcomes at lower costs, with potential economic benefits for healthcare institutions.